Clinical Trial Update: Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CMB305 with atezolizumab versus atezolizumab alone in various sarcomas has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liposarcoma
• Myxoid Round Cell Liposarcoma
• Sarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• CMB305

Snippet

Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 2 | Status: TERMINATED | Results posted: 2020-05-14